Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neelu Kaila

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Pharmaceutical Patent Analyst|November 7, 2014
New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013Atli Thorarensen, Neelu Kaila
The Journal of Organic Chemistry|October 30, 2009
Bromodecarboxylation of quinoline salicylic acids: increasing the diversity of accessible substituted quinolinesKristin Janz, Neelu Kaila
Expert Opinion on Therapeutic Patents|April 23, 2010
Selectin inhibitors: a patent reviewPatricia W Bedard, Neelu Kaila
Medicinal Research Reviews|October 9, 2002
Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitorsNeelu Kaila, Bert E Thomas
Expert Opinion on Therapeutic Patents|May 6, 2021
Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020)Ian D Linney, Neelu Kaila
Recent Patents on Inflammation & Allergy Drug Discovery|February 2, 2012
The 2010 patent landscape for spleen tyrosine kinase inhibitorsAlessandro F Moretto, Christoph Dehnhardt, Neelu Kaila, et al.
The Journal of Biological Chemistry|January 6, 2012
Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinaseJustin Hall, Ann Aulabaugh, Francis Rajamohan, et al.
Journal for Immunotherapy of Cancer|July 30, 2025
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockadeDavid N Ciccone, Fu-Shan Kuo, Scott Boiko, et al.
Journal of Medicinal Chemistry|April 5, 2002
Beta-C-mannosides as selectin inhibitorsNeelu Kaila, Lihren Chen, Bert E Thomas, et al.
Journal of Vascular Surgery|September 5, 2006
Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosisDaniel D Myers, Peter K Henke, Patricia W Bedard, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Pharmaceutical Patent Analyst|November 7, 2014
New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013Atli Thorarensen, Neelu Kaila
The Journal of Organic Chemistry|October 30, 2009
Bromodecarboxylation of quinoline salicylic acids: increasing the diversity of accessible substituted quinolinesKristin Janz, Neelu Kaila
Expert Opinion on Therapeutic Patents|April 23, 2010
Selectin inhibitors: a patent reviewPatricia W Bedard, Neelu Kaila
Medicinal Research Reviews|October 9, 2002
Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitorsNeelu Kaila, Bert E Thomas
Expert Opinion on Therapeutic Patents|May 6, 2021
Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020)Ian D Linney, Neelu Kaila
Recent Patents on Inflammation & Allergy Drug Discovery|February 2, 2012
The 2010 patent landscape for spleen tyrosine kinase inhibitorsAlessandro F Moretto, Christoph Dehnhardt, Neelu Kaila, et al.
The Journal of Biological Chemistry|January 6, 2012
Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinaseJustin Hall, Ann Aulabaugh, Francis Rajamohan, et al.
Journal for Immunotherapy of Cancer|July 30, 2025
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockadeDavid N Ciccone, Fu-Shan Kuo, Scott Boiko, et al.
Journal of Medicinal Chemistry|April 5, 2002
Beta-C-mannosides as selectin inhibitorsNeelu Kaila, Lihren Chen, Bert E Thomas, et al.
Journal of Vascular Surgery|September 5, 2006
Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosisDaniel D Myers, Peter K Henke, Patricia W Bedard, et al.
Pageof 4